LT2970336T - Tetrahidropiroltiazino junginiai - Google Patents

Tetrahidropiroltiazino junginiai

Info

Publication number
LT2970336T
LT2970336T LTEP14712875.5T LT14712875T LT2970336T LT 2970336 T LT2970336 T LT 2970336T LT 14712875 T LT14712875 T LT 14712875T LT 2970336 T LT2970336 T LT 2970336T
Authority
LT
Lithuania
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
Prior art date
Application number
LTEP14712875.5T
Other languages
English (en)
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Leonard Larry Winneroski Jr.
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT2970336T publication Critical patent/LT2970336T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP14712875.5T 2013-03-12 2014-03-04 Tetrahidropiroltiazino junginiai LT2970336T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (en) 2013-03-12 2014-03-04 Tetrahydropyrrolothiazine compounds

Publications (1)

Publication Number Publication Date
LT2970336T true LT2970336T (lt) 2018-01-10

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14712875.5T LT2970336T (lt) 2013-03-12 2014-03-04 Tetrahidropiroltiazino junginiai

Country Status (38)

Country Link
US (3) US8841293B1 (lt)
EP (1) EP2970336B1 (lt)
JP (1) JP6095844B2 (lt)
KR (1) KR101688761B1 (lt)
CN (1) CN105026404B (lt)
AP (1) AP2015008713A0 (lt)
AR (1) AR094918A1 (lt)
BR (1) BR112015018738A8 (lt)
CA (1) CA2898500C (lt)
CL (1) CL2015002529A1 (lt)
CR (1) CR20150418A (lt)
CY (1) CY1119585T1 (lt)
DK (1) DK2970336T3 (lt)
EA (1) EA026006B1 (lt)
ES (1) ES2653421T3 (lt)
HK (1) HK1212694A1 (lt)
HR (1) HRP20171851T1 (lt)
HU (1) HUE037487T2 (lt)
IL (1) IL240903B (lt)
JO (1) JO3317B1 (lt)
LT (1) LT2970336T (lt)
MA (1) MA38390B1 (lt)
ME (1) ME02910B (lt)
MX (1) MX2015012628A (lt)
MY (1) MY180083A (lt)
NO (1) NO3039297T3 (lt)
NZ (1) NZ712207A (lt)
PE (1) PE20151542A1 (lt)
PH (1) PH12015502031A1 (lt)
PL (1) PL2970336T3 (lt)
PT (1) PT2970336T (lt)
RS (1) RS56645B1 (lt)
SG (1) SG11201507499XA (lt)
SI (1) SI2970336T1 (lt)
TN (1) TN2015000340A1 (lt)
TW (1) TWI593692B (lt)
UA (1) UA112941C2 (lt)
WO (1) WO2014143579A1 (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
EP2912041B1 (en) 2012-10-26 2016-12-14 Eli Lilly and Company Tetrahydropyrrolothiazine derivatives as bace inhibitors
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft デュアルatx/ca阻害剤としての新規な二環式化合物
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
EP3555086B1 (en) 2016-12-15 2021-09-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β-セクレターゼ阻害剤としてのチアジン誘導体および使用方法
CA3047287A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
ES2910367T3 (es) * 2016-12-15 2022-05-12 Amgen Inc Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso
MX2019007101A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (en) * 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
TWI332005B (en) 2005-06-14 2010-10-21 Schering Corp Aspartyl protease inhibitors
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
CA2711655C (en) 2008-01-18 2013-03-05 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
AU2009239535A1 (en) * 2008-04-22 2009-10-29 Schering Corporation Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
MY180083A (en) 2020-11-20
CA2898500A1 (en) 2014-09-18
SI2970336T1 (sl) 2017-11-30
IL240903A0 (en) 2015-10-29
HRP20171851T1 (hr) 2018-01-12
RS56645B1 (sr) 2018-03-30
NO3039297T3 (lt) 2018-03-10
EA026006B1 (ru) 2017-02-28
CR20150418A (es) 2015-09-16
CN105026404A (zh) 2015-11-04
BR112015018738A8 (pt) 2018-01-23
AP2015008713A0 (en) 2015-09-30
JP6095844B2 (ja) 2017-03-15
TW201520217A (zh) 2015-06-01
PH12015502031B1 (en) 2016-01-18
CL2015002529A1 (es) 2016-03-28
PL2970336T3 (pl) 2018-03-30
PE20151542A1 (es) 2015-10-28
TN2015000340A1 (en) 2017-01-03
DK2970336T3 (da) 2017-11-13
JP2016512252A (ja) 2016-04-25
US8841293B1 (en) 2014-09-23
PH12015502031A1 (en) 2016-01-18
KR101688761B1 (ko) 2016-12-21
PT2970336T (pt) 2017-12-21
AU2014228351A1 (en) 2015-09-17
ME02910B (me) 2018-04-20
HUE037487T2 (hu) 2018-08-28
EP2970336B1 (en) 2017-10-04
US20140275044A1 (en) 2014-09-18
SG11201507499XA (en) 2015-10-29
NZ712207A (en) 2019-09-27
WO2014143579A1 (en) 2014-09-18
KR20150119070A (ko) 2015-10-23
UA112941C2 (uk) 2016-11-10
EP2970336A1 (en) 2016-01-20
US20150157641A1 (en) 2015-06-11
AR094918A1 (es) 2015-09-09
CA2898500C (en) 2017-11-14
JO3317B1 (ar) 2019-03-13
TWI593692B (zh) 2017-08-01
ES2653421T3 (es) 2018-02-07
US8987254B2 (en) 2015-03-24
MX2015012628A (es) 2016-07-07
CN105026404B (zh) 2016-11-23
BR112015018738A2 (pt) 2017-07-18
IL240903B (en) 2018-12-31
EA201591491A1 (ru) 2016-01-29
HK1212694A1 (zh) 2016-06-17
CY1119585T1 (el) 2018-03-07
US20140350245A1 (en) 2014-11-27
MA38390B1 (fr) 2020-01-31
MA38390A1 (fr) 2018-08-31

Similar Documents

Publication Publication Date Title
HRP20171851T1 (hr) Spojevi tetrahidropirolotiazina
HK1222658A1 (zh) 氰基三唑化合物
GB201309085D0 (en) Compounds
GB201302927D0 (en) Compounds
GB201310542D0 (en) Compounds
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201319363D0 (en) Compounds
GB201317619D0 (en) Compounds
GB201312901D0 (en) Compounds
GB201311953D0 (en) Compounds
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2948457A4 (en) COMPOUNDS
GB201318461D0 (en) Compounds
GB201316014D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201306794D0 (en) Compounds
GB201317118D0 (en) Compounds
GB201316717D0 (en) Compounds
GB201315947D0 (en) Compounds
GB201315254D0 (en) Compounds
GB201315253D0 (en) Compounds
GB201314681D0 (en) Compounds
GB201314700D0 (en) Compounds